Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AiboticsAIBT -3.33% EV-to-EBIT is -0.76 as of Aug. 10, 2026. The stock has 1 warning sign investors should review. Among 637 Travel & Leisure companies, Aibotics ranks worse than 156985.71% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aibotics's Enterprise Value for the quarter that ended in Mar. 2026 was $1.72 Mil.
Aibotics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aibotics EV-to-EBIT Related Terms
Aibotics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Aibotics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Leisure subindustry, Aibotics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aibotics EV-to-EBIT vs Travel & Leisure Industry
For the Travel & Leisure industry and Consumer Cyclical sector, Aibotics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aibotics's EV-to-EBIT falls into.
Aibotics's current Enterprise Value is $1.37 Mil.
Aibotics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aibotics (AIBT) has a EV-to-EBIT of -0.76 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aibotics and its competitors. According to the industry distribution chart, Aibotics ranks #999999 out of 637 companies in the Travel & Leisure industry.
Is Aibotics' EV-to-EBIT too high?
Aibotics' current EV-to-EBIT is -0.76. Based on the distribution chart, Aibotics ranks #999999 out of 637 companies in the Travel & Leisure industry, which is in the bottom quartile relative to peers.
How does Aibotics' EV-to-EBIT compare to SPQS and TRUG?
According to the Travel & Leisure industry distribution chart, Aibotics ranks #999999 out of 637 companies for EV-to-EBIT. This places Aibotics in the lower half of its industry. The industry median EV-to-EBIT is 14.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Travel & Leisure company?
The median EV-to-EBIT among Travel & Leisure companies is 14.52, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aibotics and its competitors. For the Travel & Leisure industry, the median EV-to-EBIT is 14.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aibotics's current EV-to-EBIT is -0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aibotics stock overvalued right now?
Aibotics (AIBT) has a current EV-to-EBIT of -0.76. The current EV-to-EBIT is -0.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aibotics (AIBT), the current EV-to-EBIT is -0.76 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aibotics Inc is a holding company specializing in artificial intelligence and robotics. It promotes the study of psychedelics for the treatment of mental health issues and supports the creation of both natural and synthetic molecules for the development of appropriate treatments. Aibotics also intends to deploy technology from its parent company, in the collection of research and clinical data to further the study of the effects of psychedelics in the treatment of mental health issues.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIBT has been successfully added to your 
